IRIS
Mancuso, Maria Elisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.262
NA - Nord America 636
SA - Sud America 493
EU - Europa 173
AF - Africa 36
Totale 2.600
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 592
SG - Singapore 591
BR - Brasile 389
VN - Vietnam 326
CN - Cina 202
AR - Argentina 50
ID - Indonesia 38
IT - Italia 37
HK - Hong Kong 31
FR - Francia 28
DE - Germania 22
EC - Ecuador 19
BD - Bangladesh 17
GB - Regno Unito 16
FI - Finlandia 13
MX - Messico 13
IQ - Iraq 12
MQ - Martinica 11
RU - Federazione Russa 10
VE - Venezuela 10
CA - Canada 9
CO - Colombia 9
UA - Ucraina 8
IE - Irlanda 7
NL - Olanda 7
AT - Austria 6
EG - Egitto 6
ZA - Sudafrica 6
IN - India 5
PK - Pakistan 5
PL - Polonia 5
TN - Tunisia 5
CL - Cile 4
IL - Israele 4
MA - Marocco 4
MY - Malesia 4
NG - Nigeria 4
PY - Paraguay 4
SE - Svezia 4
TR - Turchia 4
AZ - Azerbaigian 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
JP - Giappone 3
KE - Kenya 3
LT - Lituania 3
OM - Oman 3
PE - Perù 3
SN - Senegal 3
UY - Uruguay 3
UZ - Uzbekistan 3
BO - Bolivia 2
HN - Honduras 2
NP - Nepal 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
ET - Etiopia 1
GT - Guatemala 1
HR - Croazia 1
JM - Giamaica 1
KH - Cambogia 1
KR - Corea 1
LB - Libano 1
NI - Nicaragua 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 2.600
Salva come PNG Salva come JPEG
Città #
Singapore 164
San Jose 136
Ho Chi Minh City 120
Ashburn 117
Beijing 100
Dallas 84
Hanoi 64
Wilmington 33
Hong Kong 31
The Dalles 25
São Paulo 22
Da Nang 17
Haiphong 17
Assago 16
Chandler 15
Helsinki 13
Thái Bình 13
Curitiba 12
Los Angeles 12
San Mateo 12
Fort-de-France 11
Ann Arbor 10
New York 10
Rio de Janeiro 10
Thái Nguyên 10
Hải Dương 9
Jakarta 9
Brasília 8
Buenos Aires 8
Santa Clara 8
Guayaquil 7
Leawood 7
Orem 7
Porto Alegre 7
Shanghai 7
Biên Hòa 6
Boardman 6
Can Tho 6
Dublin 6
Frankfurt am Main 6
Amsterdam 5
Baghdad 5
Belo Horizonte 5
Campinas 5
Hillsboro 5
Lawrence 5
Princeton 5
Ribeirão Preto 5
Uberlândia 5
Woodbridge 5
Benin City 4
Cairo 4
Contagem 4
Dhaka 4
Duque de Caxias 4
Ha Long 4
Johannesburg 4
Manaus 4
Manchester 4
Mexico City 4
Milan 4
Montreal 4
Nha Trang 4
Paris 4
Posadas 4
Quito 4
Toronto 4
Vila Velha 4
Warsaw 4
Anápolis 3
Bandung 3
Caxias do Sul 3
Dakar 3
Fortaleza 3
Guarulhos 3
Istanbul 3
Itaquaquecetuba 3
Kyiv 3
Limeira 3
Lấp Vò 3
Maceió 3
Naples 3
Nova Iguaçu 3
Passo Fundo 3
Praia Grande 3
Santo André 3
Santo Domingo 3
Tashkent 3
Tunis 3
Al Mansurah 2
Asunción 2
Atlanta 2
Baku 2
Barquisimeto 2
Boston 2
Buffalo 2
Burzaco 2
Bến Tre 2
Cabo Frio 2
Cachoeira do Sul 2
Totale 1.389
Salva come PNG Salva come JPEG
Nome #
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 78
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy 67
High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study 67
Mortality and causes of death in Italian persons with haemophilia, 1990-2007 58
Uniportal and three-portal video-assisted thoracic surgery lobectomy: analysis of the Italian video-assisted thoracic surgery group database 57
Compromised Lung Volume and Hemostatic Abnormalities in COVID-19 Pneumonia: Results from an Observational Study on 510 Consecutive Patients 56
What counts more: the patient, the surgical technique, or the hospital? A multivariable analysis of factors affecting perioperative complications of pulmonary lobectomy by video-assisted thoracoscopic surgery from a large nationwide registry 52
Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A 51
Comparison of thrombin generation for paired-platelet-rich plasma collected with and without corn trypsin inhibitor from hemophiliacs treated with factor-VIII inhibitor bypassing agents 41
Severe hemophilia with mild bleeding phenotype : molecular characterization and global coagulation profile 41
Predicting a Prolonged Air Leak After Video-Assisted Thoracic Surgery, Is It Really Possible? 40
Ageing successfully with haemophilia : A multidisciplinary programme 39
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study 37
Peri-operative and post-operative management of haemophiliac patients without inhibitors 37
Association study between XRCC1 gene polymorphisms and sporadic amyotrophic lateral sclerosis 37
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 35
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A 34
Orthopaedic management of haemophilia arthropathy of the ankle 34
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders 34
Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors 33
Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia 33
Peri-operative and post-operative management of haemophiliac patients with inhibitors 32
Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases 32
Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A : a patient-level meta-analysis 32
Arteriovenous fistula as stable venous access in children with severe haemophilia 32
Deep intronic variations may cause mild hemophilia A 32
Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype 31
A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients : evidence for a founder effect 31
F8 mRNA studies in haemophilia A patients with different splice site mutations 30
Global Emerging HEmophilia Panel (GEHEP): a multinational collaboration for Advancing hemophilia research and treatment 30
Dental surgery in inherited bleeding disorders with minimal factor support: commentary 30
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors 30
Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis 30
A catastrophic case of skin gangrene 29
Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy 29
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study 29
Synoviorthesis in haemophilia patients with inhibitors 29
Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A 29
Venous access in haemophilic children: choice and management 28
Increased VEGF levels in a case of papillary tumor of the pineal region with intracranial hemorrhage: A potential surrogate indicator of tumor angiogenesis and aggressiveness? 28
Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 28
Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A 28
Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management 28
Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs : a review of 116 procedures at a single institution 27
Haemophilia care in children - benefits of early prophylaxis for inhibitor prevention 27
X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers 27
Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry 26
Congenital afibrinogenemia 26
Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors 26
Applying a deliberation model to the analysis of consultations in haemophilia: Implications for doctor-patient communication 26
Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients 26
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study 26
Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteratura 25
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study 24
Handwriting Analysis in Children and Adolescents with Hemophilia : A Pilot Study 24
Prevention of arthropathy in haemophilia: prophylaxis 24
Results from a large multinational clinical trial (guardian (TM) 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy 24
Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors 24
Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients 24
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors 23
Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release 23
Polypharmacy in older adults with severe haemophilia 23
Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up 23
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 23
Integrated postural analysis in children with haemophilia 22
Factor VIII products and inhibitor development in severe hemophilia A 22
High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C 22
Barriers to primary prophylaxis in haemophilic children: the issue of the venous access 22
The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study 22
Rescue FVIII replacement to secure haemostasis in a patient with haemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement 22
Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters 22
Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease 21
Radiosynoviorthesis in children with haemophilia 20
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors 20
Synovitis and joint health in patients with haemophilia: Statements from a European e‐Delphi consensus study 20
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial 20
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort 20
Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis 19
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing 19
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort 19
PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A 18
Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: Considerations on the differentiation between the 2 circulating anticoagulants 18
Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica 18
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice 17
Investigational drugs for coagulation disorders 17
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication 15
Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study 15
The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH 15
The thrombin generation assay distinguishes inhibitor from non‐inhibitor patients with severe haemophilia A 14
Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A 14
BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study 12
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice 11
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors 11
Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents 10
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis 9
Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients 9
Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B 7
Totale 2.701
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.321
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 5 1 6
2021/202228 1 0 0 7 0 0 2 6 1 3 7 1
2022/202350 12 1 5 4 2 4 0 5 11 6 0 0
2023/202445 2 7 8 1 1 6 0 0 2 0 9 9
2024/202580 8 0 1 2 1 7 4 5 10 30 5 7
2025/20262.431 211 121 278 571 194 85 345 269 236 121 0 0
Totale 2.701